Interleukins in liver disease treatment

doi:10.4254/wjh.v16.i2.140

Advanced Search

BPG is committed to discovery and dissemination of knowledge

Home / Archive / Volume 16, Issue 2

This Article

Academic Content and Language Evaluation of This Article

CrossCheck and Google Search of This Article

Academic Rules and Norms of This Article

Citation of this article

Corresponding Author of This Article

Research Domain of This Article

Article-Type of This Article

Open-Access Policy of This Article

Times Cited Counts in Google of This Article

Number of Hits and Downloads for This Article

Total Article Views (1581)

All Articles published online

The chart showing PDF series, WORD series, HTML series, Tables (1-3) series.

Item

Count

PDF

WORD

HTML

1226

Tables (1-3)

Sum=1368

Publishing Process of This Article

The chart showing Browse series, Download series.

Item

Count

Browse

Download

114

Sum=166

Feb 27, 2024 (publication date) through Jun 9, 2024

Times Cited of This Article

Times Cited (0)

Journal Information of This Article

Publication Name

World Journal of Hepatology

ISSN

1948-5182

Publisher of This Article

Baishideng Publishing Group Inc, 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA

Editorial

World J Hepatol. Feb 27, 2024; 16(2): 140-145
Published online Feb 27, 2024. doi: 10.4254/wjh.v16.i2.140

Table 3 Interleukin-mediated therapies in liver disease

Clinical trials	Phase	Liver disease	Interleukin therapy
NCT00565539	1	Chronic hepatitis C virus (HCV) infection	PEGylated recombinant interleukin 29 (PEG-rIL-29) or in combination with daily oral ribavirin (an antiviral drug)
NCT03882307	1	Hepatitis C virus (HCV) infection	Test the association of serum levels of IL-6 and TGF-β in response to antiviral therapy (sofosbuvir and daclatasvir) for chronic hepatitis C patients
NCT02431312	1	Chronic hepatitis B	Evaluate the safety, tolerability, and immunogenicity of dose combinations of INO-1800 (DNA plasmids encoding hepatitis B surface antigen and hepatitis B core antigen) and INO-9112 (DNA plasmid encoding human interleukin 12) delivered by electroporation
NCT02655510	1/2	Alcoholic hepatitis	To test the efficacy of F-652, a recombinant fusion protein containing human IL-22 and human immunoglobulin G2 (IgG2)-Fc produced in CHO cells in serum-free culture
NCT03775109	2	Alcoholic hepatitis	To evaluate the potential benefits of the IL-1β antibody Canakinumab in the treatment of alcoholic hepatitis
NCT01988506	2	Autoimmune hepatitis, and other autoimmune and auto-inflammatory diseases	Low-dose IL-2 to induce regulatory T cells
NCT00196586	2	Chronic hepatitis C	Evaluate the efficacy and safety of the addition of IL-2 to pegylated interferon α-2a and ribavirin in patients with HCV/HIV coinfection
NCT01697501	3	Chronic hepatitis B	Evaluating the IL-28B polymorphism in patients with HBeAg-negative chronic hepatitis B treated with pegylated interferon α-2a
NCT03090035	3	Chronic hepatitis C	Test IL-28B (rs12979860) genotypes in patients with chronic hepatitis C infection treated with pegylated interferon α2 plus ribavirin
NCT02360592	4	Chronic hepatitis B	Evaluate the efficacy and safety of interferon α-2b therapy plus IL-2 and hepatitis B therapeutic vaccine compared to interferon α-2b alone
NCT03734783	Observational	Chronic hepatitis B	Investigate the levels of IL-35-secreting B regulatory cells in peripheral blood cells in patients with chronic hepatitis B and their functions on Th1 and Th2 cell levels

IL: Interleukins.

Citation: Yang M, Zhang CY. Interleukins in liver disease treatment. World J Hepatol 2024; 16(2): 140-145
URL: https://www.wjgnet.com/1948-5182/full/v16/i2/140.htm
DOI: https://dx.doi.org/10.4254/wjh.v16.i2.140